Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 1,764,114 Bristol-Myers Squibb (NYSE:BMY)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,764,114 shares of the biopharmaceutical company's stock, valued at approximately $99,778,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.09% of Bristol-Myers Squibb as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pinnacle Wealth Planning Services Inc. grew its holdings in Bristol-Myers Squibb by 8.4% during the fourth quarter. Pinnacle Wealth Planning Services Inc. now owns 4,514 shares of the biopharmaceutical company's stock valued at $255,000 after purchasing an additional 349 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $188,000. Leigh Baldwin & CO. LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $534,000. Polar Asset Management Partners Inc. bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $16,651,000. Finally, Hall Capital Management Co. Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth about $329,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded up $0.41 during midday trading on Friday, hitting $48.26. 20,755,167 shares of the company's stock were exchanged, compared to its average volume of 13,146,904. The company has a market cap of $98.21 billion, a P/E ratio of -10.92, a PEG ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a 50-day moving average price of $50.71 and a two-hundred day moving average price of $55.46. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Bristol-Myers Squibb's revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. On average, equities research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.14%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently 92.88%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Jefferies Financial Group dropped their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Finally, Piper Sandler began coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $58.00.

Insider Activity

In other news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.